GlycoMimetics Inc Asset Resilience Ratio
GlycoMimetics Inc asset resilience ratio. GlycoMimetics Inc (GLYC) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can GlycoMimetics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GlycoMimetics Inc (2011–2017)
Asset resilience ratio of GlycoMimetics Inc from 2011 to 2017. This chart shows how GlycoMimetics Inc's Asset Resilience Ratio has changed over time. Read GlycoMimetics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GlycoMimetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GLYC total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GlycoMimetics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
GlycoMimetics Inc Industry Peers by Asset Resilience Ratio
Compare GlycoMimetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
GlycoMimetics Inc Asset Resilience Ratio by Year (2011–2017)
GlycoMimetics Inc asset resilience ratio by year from 2011 to 2017. The table below shows the annual Asset Resilience Ratio data for GlycoMimetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $128.58 Million | -- |
| 2016-12-31 | 0.03% | $10.65K | $42.39 Million | +0.01pp |
| 2015-12-31 | 0.02% | $9.27K | $48.46 Million | -0.01pp |
| 2014-12-31 | 0.03% | $16.29K | $57.26 Million | +0.01pp |
| 2013-12-31 | 0.02% | $1.00K | $5.28 Million | -0.43pp |
| 2012-12-31 | 0.45% | $83.00K | $18.42 Million | +0.20pp |
| 2011-12-31 | 0.25% | $73.00K | $28.91 Million | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.